Special Issue "Antibody Engineering for Cancer Immunotherapy"

Silvia Crescioli; Ann L White; Sophia N Karagiannis

doi:10.3390/antib11020029

Special Issue "Antibody Engineering for Cancer Immunotherapy"

Silvia Crescioli, Ann L White, Sophia N Karagiannis

Dermatology

Research output: Contribution to journal › Editorial › peer-review

2 Citations (Scopus)

58 Downloads (Pure)

Abstract

Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...].

Original language	English
Article number	29
Journal	Antibodies (Basel, Switzerland)
Volume	11
Issue number	2
DOIs	https://doi.org/10.3390/antib11020029
Publication status	Published - 15 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/antib11020029

Crescioli White and Karagiannis antibodies-11-00029Licence: CC BY

Cite this

@article{3bd656711ab143cbbec4570ed7579779,

title = "Special Issue {"}Antibody Engineering for Cancer Immunotherapy{"}",

abstract = "Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...].",

author = "Silvia Crescioli and White, {Ann L} and Karagiannis, {Sophia N}",

year = "2022",

month = apr,

day = "15",

doi = "10.3390/antib11020029",

language = "English",

volume = "11",

journal = "Antibodies (Basel, Switzerland)",

issn = "2073-4468",

publisher = "MDPI AG",

number = "2",

}

TY - JOUR

T1 - Special Issue "Antibody Engineering for Cancer Immunotherapy"

AU - Crescioli, Silvia

AU - White, Ann L

AU - Karagiannis, Sophia N

PY - 2022/4/15

Y1 - 2022/4/15

N2 - Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...].

AB - Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...].

UR - http://www.scopus.com/inward/record.url?scp=85129097799&partnerID=8YFLogxK

U2 - 10.3390/antib11020029

DO - 10.3390/antib11020029

M3 - Editorial

C2 - 35466282

SN - 2073-4468

VL - 11

JO - Antibodies (Basel, Switzerland)

JF - Antibodies (Basel, Switzerland)

IS - 2

M1 - 29

ER -

Special Issue "Antibody Engineering for Cancer Immunotherapy"

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this